Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
Despoina Aslanoglou, Suzanne Bertera, Marta Sánchez‐Soto, R. Benjamin Free, Jeongkyung Lee, Wei Zong, Xiangning Xue, Shristi Shrestha, Marcela Briššová, Ryan W. Logan, Claes B. Wollheim, Massimo Trucco, Vijay Yechoor, David R. Sibley, Rita Bottino, Zachary Freyberg
Abstract
Abstract Dopamine (DA) and norepinephrine (NE) are catecholamines primarily studied in the central nervous system that also act in the pancreas as peripheral regulators of metabolism. Pancreatic catecholamine signaling has also been increasingly implicated as a mechanism responsible for the metabolic disturbances produced by antipsychotic drugs (APDs). Critically, however, the mechanisms by which catecholamines modulate pancreatic hormone release are not completely understood. We show that human and mouse pancreatic α- and β-cells express the catecholamine biosynthetic and signaling machinery, and that α-cells synthesize DA de novo. This locally-produced pancreatic DA signals via both α- and β-cell adrenergic and dopaminergic receptors with different affinities to regulate glucagon and insulin release. Significantly, we show DA functions as a biased agonist at α 2A -adrenergic receptors, preferentially signaling via the canonical G protein-mediated pathway. Our findings highlight the interplay between DA and NE signaling as a novel form of regulation to modulate pancreatic hormone release. Lastly, pharmacological blockade of DA D 2 -like receptors in human islets with APDs significantly raises insulin and glucagon release. This offers a new mechanism where APDs act directly on islet α- and β-cell targets to produce metabolic disturbances.